Garcinol in gastrointestinal cancer prevention: recent advances and future prospects.
J Cancer Res Clin Oncol
; 150(7): 370, 2024 Jul 27.
Article
in En
| MEDLINE
| ID: mdl-39066940
ABSTRACT
Gastrointestinal cancers continue to pose a significant global health challenge, with millions of new cases diagnosed each year. Despite advancements in treatment, the prognosis for many patients remains poor. This article explores the potential of garcinol, a polyisoprenylated benzophenone found in various Garcinia species, as a therapeutic agent against gastrointestinal malignancies. The objective is to review recent research on garcinol's anticancer properties, its mechanisms of action, and safety aspects. Garcinol exhibits anticancer effects in esophageal, gastric, colorectal, pancreatic, and liver cancers by inhibiting metastasis, inducing apoptosis, and targeting key molecular pathways in cancer progression. Nanotechnology is explored as a means to enhance garcinol delivery and efficacy. Safety assessments suggest a promising toxicity profile. Garcinol shows significant potential as a natural therapeutic agent for gastrointestinal cancers, and future research is needed on optimizing its delivery, exploring synergistic combinations, and conducting clinical trials to validate its efficacy and safety for clinical applications.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Terpenes
/
Gastrointestinal Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
J Cancer Res Clin Oncol
Year:
2024
Document type:
Article
Affiliation country:
India
Country of publication:
Germany